Primagen and Delphic Enter Into Distribution and Licensing Agreement for a Mitochondrial Toxicity Assay in the UK and Ireland

21-Oct-2003
Primagen Holding B.V., a provider of molecular diagnostic tests for infections, AIDS and cancer, announced today that it has entered into an exclusive distribution and licensing agreement with Delphic Europe diagnostics Ltd (www.delphiceurope.com) to promote its Retina(tm) Mitox(tm) mitochondrial toxicity assay in the UK and Ireland. "The agreement with Delphic is further confirmation of our commitment to reach a worldwide market for our products," said Dr. Jos Rijntjes, Chief Commercial Officer of Primagen. "It is our mission to improve the treatment of individual patients with our own molecular tests that have high predictive value. The collaboration with Delphic will help to ensure that our technology is successful in reaching patients and physicians in the clinical setting." "The collaboration with Primagen fits perfectly with our goal of making individualized treatment a reality for the clinical management of every patient," said Tim Leaver, Managing Director of Delphic. "Primagen's solution-driven approach to diagnostics complements our own aim of providing a link between the best possible science and its clinical utility. The Retina(tm) Mitox(tm) assay is an important addition to the diagnostics portfolio and will help us to realise our shared goal of facilitating the best possible therapeutic outcomes for patients."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures